CytoVeris reports that the company has been awarded a National Cancer Institute Small Business Innovation Research (SBIR) Grant from the National Institute of Health (NIH) to establish the feasibility of its AI-powered UV-autofluorescence technology in patients with bladder cancer.
“Our innovative platform technology combines artificial intelligence with advanced imaging and has the unique flexibility to be applied to multiple disease areas,” said Dr. Alan Kersey, CEO and Founder of CytoVeris.